Cigna Cash & Equivalents decreased by 8.3% to $7.04B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 15.5%, from $8.33B to $7.04B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -5.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.82B | $3.48B | $5.08B | $4.42B | $4.42B | $7.08B | $5.92B | $7.94B | $9.59B | $8.50B | $7.82B | $8.44B | $6.79B | $5.89B | $7.55B | $8.33B | $4.33B | $6.03B | $7.68B | $7.04B |
| QoQ Change | — | -8.8% | +45.9% | -12.9% | -0.1% | +60.1% | -16.3% | +33.9% | +20.8% | -11.4% | -7.9% | +7.9% | -19.6% | -13.3% | +28.2% | +10.4% | -48.1% | +39.2% | +27.4% | -8.3% |
| YoY Change | — | — | — | — | +15.7% | +103.2% | +16.6% | +79.4% | +116.8% | +20.0% | +32.0% | +6.4% | -29.2% | -30.7% | -3.5% | -1.2% | -36.2% | +2.3% | +1.7% | -15.5% |